Alexander Sulakvelidze
President & Chief Executive Officer Intralytix, Inc.
Seminars
Wednesday 25th March 2026
From Discovery to Clinic and Everything in Between: Intralytix’s Path to Phage Therapies and Microbiome Modulation
11:30 am
- Outlining how Intralytix evolved from its origins in human therapeutic phage development to becoming a global pioneer in food safety and environmental biocontrol, leveraging these commercial successes to re-enter the human health space with multiple clinical-stage phage therapy programs
- Examining the ongoing technical and regulatory challenges facing the field, including the identification of potent therapeutic phages, ensuring scalability, and meeting cGMP standards under 21 CFR 111/117 and 210/211 to bridge discovery and clinical translation
- Showcasing Intralytix’s proprietary PhageSelector™ and PhageEngine™ platforms, which integrate high-throughput screening, data science, and AI to refine phagehost pairing, guide cocktail formulation, and streamline scale-up for therapeutic and microbiome-modulating applications
